INTRODUCTION: Imatinib mesylate (Gleevec) is a well known drug for treating chronic myeloid leukemia and gastrointestinal stromal tumors. Its active ingredient, imatinib ([4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide), blocks the activity of several tyrosine kinases. Here we labeled imatinib with carbon-11 as a tool for determining the drug distribution and pharmacokinetics of imatinib, and we carried out positron emission tomography (PET) studies in baboons. METHODS: [N-(11)C-methyl]imatinib was synthesized from [(11)C]methyl iodide and norimatinib was synthesized by the demethylation of imatinib (isolated from Gleevec tablets) according to a patent procedure [Collins JM, Klecker RW Jr, Anderson LW. Imaging of drug accumulation as a guide to antitumor therapy. US Patent 20030198594A1, 2003]. Norimatinib was also synthesized from the corresponding amine and acid. PET studies were carried out in three baboons to measure pharmacokinetics in the brain and peripheral organs and to determine the effect of a therapeutic dose of imatinib. Log D and plasma protein binding were also measured. RESULTS: [N-(11)C-methyl]imatinib uptake in the brain is negligible (consistent with P-glycoprotein-mediated efflux); it peaks and clears rapidly from the heart, lungs and spleen. Peak uptake and clearance occur more slowly in the liver and kidneys, followed by accumulation in the gallbladder and urinary bladder. Pretreatment with imatinib did not change uptake in the heart, lungs, kidneys and spleen, and increased uptake in the liver and gallbladder. CONCLUSIONS: [N-(11)C-methyl]imatinib has potential for assessing the regional distribution and kinetics of imatinib in the human body to determine whether the drug targets tumors and to identify other organs to which the drug or its labeled metabolites distribute. Paired with tracers such as 2'deoxy-2'-[(18)F]fluoro-D-glucose ((18)FDG) and 3'deoxy-3'-[(18)F]fluorothymidine ((18)FLT), [N-(11)C-methyl]imatinib may be a useful radiotracer for planning chemotherapy, for monitoring response to treatment and for assessing the role of drug pharmacokinetics in drug resistance.
INTRODUCTION:Imatinib mesylate (Gleevec) is a well known drug for treating chronic myeloid leukemia and gastrointestinal stromal tumors. Its active ingredient, imatinib ([4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]phenyl]benzamide), blocks the activity of several tyrosine kinases. Here we labeled imatinib with carbon-11 as a tool for determining the drug distribution and pharmacokinetics of imatinib, and we carried out positron emission tomography (PET) studies in baboons. METHODS:[N-(11)C-methyl]imatinib was synthesized from [(11)C]methyl iodide and norimatinib was synthesized by the demethylation of imatinib (isolated from Gleevec tablets) according to a patent procedure [Collins JM, Klecker RW Jr, Anderson LW. Imaging of drug accumulation as a guide to antitumor therapy. US Patent 20030198594A1, 2003]. Norimatinib was also synthesized from the corresponding amine and acid. PET studies were carried out in three baboons to measure pharmacokinetics in the brain and peripheral organs and to determine the effect of a therapeutic dose of imatinib. Log D and plasma protein binding were also measured. RESULTS:[N-(11)C-methyl]imatinib uptake in the brain is negligible (consistent with P-glycoprotein-mediated efflux); it peaks and clears rapidly from the heart, lungs and spleen. Peak uptake and clearance occur more slowly in the liver and kidneys, followed by accumulation in the gallbladder and urinary bladder. Pretreatment with imatinib did not change uptake in the heart, lungs, kidneys and spleen, and increased uptake in the liver and gallbladder. CONCLUSIONS:[N-(11)C-methyl]imatinib has potential for assessing the regional distribution and kinetics of imatinib in the human body to determine whether the drug targets tumors and to identify other organs to which the drug or its labeled metabolites distribute. Paired with tracers such as 2'deoxy-2'-[(18)F]fluoro-D-glucose ((18)FDG) and 3'deoxy-3'-[(18)F]fluorothymidine ((18)FLT), [N-(11)C-methyl]imatinib may be a useful radiotracer for planning chemotherapy, for monitoring response to treatment and for assessing the role of drug pharmacokinetics in drug resistance.
Authors: M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher Journal: Am J Pathol Date: 2000-03 Impact factor: 4.307
Authors: E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon Journal: J Pharmacol Exp Ther Date: 2000-10 Impact factor: 4.030
Authors: Martin H Cohen; Grant Williams; John R Johnson; John Duan; Jogarao Gobburu; Atiqur Rahman; Kimberly Benson; John Leighton; Sung K Kim; Rebecca Wood; Mark Rothmann; Gang Chen; Khin Maung U; Ann M Staten; Richard Pazdur Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: D A Tuveson; N A Willis; T Jacks; J D Griffin; S Singer; C D Fletcher; J A Fletcher; G D Demetri Journal: Oncogene Date: 2001-08-16 Impact factor: 9.867
Authors: Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force Journal: Nat Med Date: 2006-07-23 Impact factor: 53.440
Authors: Bhushan Nagar; William G Bornmann; Patricia Pellicena; Thomas Schindler; Darren R Veach; W Todd Miller; Bayard Clarkson; John Kuriyan Journal: Cancer Res Date: 2002-08-01 Impact factor: 12.701
Authors: Kun-Eek Kil; Anat Biegon; Yu-Shin Ding; Andre Fischer; Richard A Ferrieri; Sung Won Kim; Deborah Pareto; Michael J Schueller; Joanna S Fowler Journal: Nucl Med Biol Date: 2009-02 Impact factor: 2.408
Authors: M A Pantaleo; S Fanti; M Nannini; S Boschi; C Nanni; A Maleddu; D Rubello; G Biasco Journal: Eur J Nucl Med Mol Imaging Date: 2008-10 Impact factor: 9.236
Authors: Athanasios P Glekas; Nagavara Kishore Pillarsetty; Blesida Punzalan; Nahida Khan; Peter Smith-Jones; Steven M Larson Journal: J Nucl Med Date: 2011-07-15 Impact factor: 10.057
Authors: Lemonitsa H Mammatas; Henk M W Verheul; N Harry Hendrikse; Maqsood Yaqub; Adriaan A Lammertsma; C Willemien Menke-van der Houven van Oordt Journal: Cell Oncol (Dordr) Date: 2014-09-24 Impact factor: 6.730
Authors: Mikhail Doubrovin; Tatiana Kochetkova; Elmer Santos; Darren R Veach; Peter Smith-Jones; Nagavarakishore Pillarsetty; Julius Balatoni; William Bornmann; Juri Gelovani; Steven M Larson Journal: J Nucl Med Date: 2010-01 Impact factor: 10.057
Authors: M A Pantaleo; L Landuzzi; G Nicoletti; C Nanni; S Boschi; G Piazzi; D Santini; M Di Battista; P Castellucci; F Lodi; S Fanti; P-L Lollini; G Biasco Journal: Clin Exp Med Date: 2009-02-19 Impact factor: 3.984